Cargando…

An appraisal of golimumab in the treatment of severe, active nonradiographic axial spondyloarthritis

Golimumab (Simponi(®)) is a fully human tumor necrosis factor α inhibitor (TNFi) antibody administered subcutaneously. In the European Union, golimumab is indicated for the treatment of adults with severe, active axial spondyloarthritis (axSpA), which includes both ankylosing spondylitis (AS) and no...

Descripción completa

Detalles Bibliográficos
Autores principales:	Paccou, Julien, Flipo, René-Marc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946857/ https://www.ncbi.nlm.nih.gov/pubmed/27468228 http://dx.doi.org/10.2147/DDDT.S91441

Ejemplares similares

Golimumab in radiographic and nonradiographic axial spondyloarthritis: a review of clinical trials
por: Toussirot, Eric, et al.
Publicado: (2016)

Golimumab in radiographic and nonradiographic axial spondyloarthritis: a review of clinical trials [Corrigendum]
Publicado: (2017)

Nonradiographic axial spondyloarthritis: clinical and therapeutic relevance
por: Ghosh, Nilasha, et al.
Publicado: (2017)

The Nonradiographic Axial Spondyloarthritis, the Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis: The Tangled Skein of Rheumatology
por: Malaviya, Anand N., et al.
Publicado: (2017)

Antiphospholipid Syndrome Associated with Nonradiographic Axial Spondyloarthritis
por: De Carvalho, Jozélio Freire, et al.
Publicado: (2021)

A Randomized, Double‐Blind, Placebo‐Controlled, Sixteen‐Week Study of Subcutaneous Golimumab in Patients With Active Nonradiographic Axial Spondyloarthritis
por: Sieper, J., et al.
Publicado: (2015)

Cortical bone loss is an early feature of nonradiographic axial spondyloarthritis
por: Neumann, Anna, et al.
Publicado: (2018)

Differentiating nonradiographic axial spondyloarthritis from its mimics: a narrative review
por: Mease, Philip, et al.
Publicado: (2022)

Predictive Factors of Clinical Response of Infliximab Therapy in Active Nonradiographic Axial Spondyloarthritis Patients
por: Lin, Zhiming, et al.
Publicado: (2015)

Discriminating Value of Calprotectin in Disease Activity and Progression of Nonradiographic Axial Spondyloarthritis and Ankylosing Spondylitis
por: Huang, Jinxian, et al.
Publicado: (2017)

The Effect of Etanercept in Nonradiographic Axial Spondyloarthritis by Stratified C‐Reactive Protein Levels
por: Tam, Hoi Ki Joshua, et al.
Publicado: (2021)

Nonradiographic axial spondyloarthritis: expanding the spectrum of an old disease: A narrative review
por: Magrey, Marina, et al.
Publicado: (2022)

Characterization of Patients With Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis in the US‐Based Corrona Registry
por: Mease, Philip J., et al.
Publicado: (2018)

Improvement of Functioning and Health With Ixekizumab in the Treatment of Active Nonradiographic Axial Spondyloarthritis in a 52‐Week, Randomized, Controlled Trial
por: Walsh, Jessica A., et al.
Publicado: (2022)

Is Treatment in Patients With Suspected Nonradiographic Axial Spondyloarthritis Effective? Six‐Month Results of a Placebo‐Controlled Trial
por: Rusman, Tamara, et al.
Publicado: (2021)

Spinal Inflammation in the Absence of Sacroiliac Joint Inflammation on Magnetic Resonance Imaging in Patients With Active Nonradiographic Axial Spondyloarthritis
por: van der Heijde, Désirée, et al.
Publicado: (2014)

Predictors of Assessment of Spondyloarthritis International Society (ASAS) Health Index in Axial Spondyloarthritis and Comparison of ASAS Health Index between Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis: Data from the Catholic Axial Spondyloarthritis COhort (CASCO)
por: Min, Hong Ki, et al.
Publicado: (2019)

A Fifty‐Two–Week, Randomized, Placebo‐Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis
por: Deodhar, Atul, et al.
Publicado: (2019)

Comparison of drug survival on adalimumab, etanercept, golimumab and infliximab in patients with axial spondyloarthritis
por: Hebeisen, Monika, et al.
Publicado: (2019)

Differences between men and women with nonradiographic axial spondyloarthritis: clinical characteristics and treatment effectiveness in a real-life prospective cohort
por: Neuenschwander, Regula, et al.
Publicado: (2020)

Discriminant validity, responsiveness and reliability of the arthritis-specific Work Productivity Survey assessing workplace and household productivity within and outside the home in patients with axial spondyloarthritis, including nonradiographic axial spondyloarthritis and ankylosing spondylitis
por: Osterhaus, Jane T, et al.
Publicado: (2014)

The prevalence and clinical characteristics of nonradiographic axial spondyloarthritis among patients with inflammatory back pain in rheumatology practices: a multinational, multicenter study
por: Burgos-Varga, Ruben, et al.
Publicado: (2016)

The assessment of the spondyloarthritis international society concept and criteria for the classification of axial spondyloarthritis and peripheral spondyloarthritis: A critical appraisal for the pediatric rheumatologist
por: Burgos-Vargas, Ruben
Publicado: (2012)

Erratum to: The prevalence and clinical characteristics of nonradiographic axial spondyloarthritis among patients with inflammatory back pain in rheumatology practices: a multinational, multicenter study
por: Burgos-Vargas, Ruben, et al.
Publicado: (2016)

Spinal radiographic progression in axial spondyloarthritis and the impact of classification as nonradiographic versus radiographic disease: Data from the Swiss Clinical Quality Management cohort
por: Hebeisen, Monika, et al.
Publicado: (2020)

Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo‐Controlled Phase III Study
por: Deodhar, Atul, et al.
Publicado: (2020)

Validation of assessment methods for the apparent diffusion coefficient in a clinical trial of axial spondyloarthritis patients treated with golimumab
por: Møller, Jakob M., et al.
Publicado: (2020)

Efficacy and safety of golimumab in patients with non-radiographic axial spondyloarthritis: a withdrawal and retreatment study (GO-BACK)
por: Weinstein, Cindy L J, et al.
Publicado: (2023)

Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis who received long-term open-label adalimumab treatment: 3-year results of the ABILITY-1 trial
por: van der Heijde, Désirée, et al.
Publicado: (2018)

Hearing loss can also be seen in patients with nonradiographic axial spondyloarthropathies as well as radiographic axial spondyloarthropathies
por: Çağlar Yağcı, Hanife, et al.
Publicado: (2023)

Persistence with golimumab in immune-mediated rheumatic diseases: a systematic review of real-world evidence in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis
por: Svedbom, Axel, et al.
Publicado: (2017)

JAK Inhibitors for the Treatment of Axial Spondyloarthritis
por: Klavdianou, Kalliopi, et al.
Publicado: (2023)

Body composition in patients with rheumatoid arthritis: a narrative literature review
por: Letarouilly, Jean-Guillaume, et al.
Publicado: (2021)

Patient Burden of Axial Spondyloarthritis
por: Strand, Vibeke, et al.
Publicado: (2017)

Uncovering the Underworld of Axial Spondyloarthritis
por: Del Vescovo, Sergio, et al.
Publicado: (2023)

Korean treatment recommendations for patients with axial spondyloarthritis
por: Seo, Mi Ryoung, et al.
Publicado: (2023)

The prevalence of fibromyalgia in axial spondyloarthritis
por: Jones, Gareth T., et al.
Publicado: (2020)

Anti-IL-17 Agents in the Treatment of Axial Spondyloarthritis
por: Atzeni, Fabiola, et al.
Publicado: (2021)

Active axial spondyloarthritis: potential role of certolizumab pegol
por: Ranatunga, Sriya, et al.
Publicado: (2014)

Targeting inflammatory pathways in axial spondyloarthritis
por: Furst, Daniel E., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_psjpjo44lt1kfm4obtcfo56gpg